Arkadios Wealth Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-250
Closed -$11K – 1808
2021
Q3
$11K Hold
250
– – ﹤0.01% 1423
2021
Q2
$12K Hold
250
– – ﹤0.01% 1488
2021
Q1
$12K Hold
250
– – ﹤0.01% 1141
2020
Q4
$13K Buy
+250
New +$12K ﹤0.01% 902

Other funds holding XPH

Arkadios Wealth Advisors's XPH Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2021, closing a stake of 250 shares — an estimated $11K sold.

Arkadios Wealth Advisors first reported a position in XPH in Q4 2020 and held it in 4 quarters. The position peaked at $13K in Q4 2020. 77 funds tracked by Wall St. Rank hold XPH as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 250 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2021, an estimated $11K.
  • Arkadios Wealth Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2020 and held it in 4 quarters.
  • Arkadios Wealth Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $13K in Q4 2020.
  • 77 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.